Table 4. Cost-Effectiveness Results by Gender and Genotype, Standard Treatment.

Genotype 1		Cost (US, $)	QALY	ICER ($/QALY)
Men	FibroTest Only	193,979	15.01	–
	FibroTest Rule In	194,447	14.82	dominated
	Immediate Treatment	194,514	15.10	5,400
	FibroTest and Biopsy	194,950	15.01	dominated
	Liver Biopsy Only	195,169	14.85	dominated
	FibroTest Rule Out	196,182	14.84	dominated
Women	FibroTest Only	213,525	16.19	–
	FibroTest Rule In	213,901	16.00	dominated
	Immediate Treatment	214,101	16.28	6,300
	FibroTest and Biopsy	214,557	16.19	dominated
	Liver Biopsy Only	214,760	16.01	dominated
	FibroTest Rule Out	215,987	16.01	dominated

(ICER: incremental cost-effectiveness ratios. dominated: strategy costs more but achieves less QALY than the previous strategy or a combination of strategies).